Tcf7l2, also known as Tcf4, is a member of the HMG-box containing T-cell factor (Tcf)/Lymphoid enhancer factor (Lef) transcription factor family of DNA binding proteins downstream of the canonical Wnt pathway [1] . In addition to its well known role during development recent evidence suggests that the Wnt pathway is implicated in stem cell homeostasis, cancer development and metabolic disorders [2] . Thus, it is not surprising, that genome wide association studies (GWAS) have identified TCF7L2 as a locus conveying an increased risk for developing type 2 diabetes (T2D) for the homozygous carrier of the minor allele [3] . Since this finding, several studies have focused on understanding the mechanism underlying the metabolic function of Tcf7l2 in organs and in pancreatic b-cells. In the small intestine, Tcf7l2-dependent Wnt signaling is essential for maintenance of proliferating cells located in the "intervillus pockets" as well as for the differentiation towards the hormone-producing enteroendocrine lineage [2] . In these cells, Tcf7l2 regulates pro-glucagon expression, precursor of glucagon-derived hormones. In the adult pancreas, cumulative evidence suggests that Tcf7l2/b-catenin signaling is critical for Glucagon-like peptide 1 (Glp-1) induced b-cell proliferation and Stromal-derived factor 1 (Sdf-1)-mediated b-cell survival [4] . Moreover, recent data indicate that alternative splicing isoforms of TCF7L2 differently regulate b-cell proliferation and glucose-dependent insulin secretion in adult human islets [5] . Despite all these efforts, many questions remain, e.g. which metabolic organ requires Wnt/Tcf7l2 signaling for its function, when is Tcf7l2 function required for organ development and homeostasis, and is Tcf7l2 function conserved between the pre-clinical mouse model and human patients? Answers to these questions will unravel the contribution of TCF7L2 to the development of diabetes. Moreover, this study revealed that full body knock-out of Tcf7l2 had no effect on embryonic development of the endocrine pancreas, the expression of b-cell genes and b-cell proliferation. The authors of this study conclude that Tcf7l2 is not important for b-cell function in mice but controls the hepatic response to perinatal and adult metabolic 
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regulates GLP-1 effects in b-cells by transcriptionally controlling its receptor. Surprisingly, the in vitro results from the Ins-1 insulinoma system cannot be confirmed directly in vivo by the postnatal expression of TCF7L2DN under the Insulin 2 promoter (bTCFDN mice) [6] . Specifically, attenuation of Wnt/b-catenin signaling shortly after birth resulted in down regulation of MafA and Pdx1 expression in islets. No alteration of b-cell mass, homeostasis and glucose control during adulthood was noted either when TCF7L2DN was expressed before or after weaning. Boj et al. found similar results when using a rat insulin promoter (RIP)-driven inducible Cre-ER T2 recombinase approach to ablate Tcf7l2 specifically in adult b-cells at weaning and did not observe b-cell dysfunction either on normal chow or high-fat diet [9] .
Moreover, this study revealed that full body knock-out of Tcf7l2 had no effect on embryonic development of the endocrine pancreas, the in line with these results and found that embryonic expression of TCFL2DN affects b-cell development and homeostasis [6] . In particular, a reduced number of pancreatic Pdx1 þ /Nkx6.1 þ double positive cells were formed, which caused an altered b-cell mass and abnormal insulin secretion in adult mice. These findings are comparable to previous data from Mitchell et al. where embryonic Tcf7l2 ablation using an Ins1-Cre driver line which is active already at embryonic day (E) 11.5 led to impaired b-cell mass and secretory function [6, 11] .
These observations emphasize that Tcf7l2 function is required when b-cells are born during pancreas development, but might also be needed to maintain b-cell homeostasis in the adult islet. Specifically, ectopic stabilization of b-catenin in pancreatic epithelium during the first transition leads to loss of Pdx1 expression, whereby inducing the stabilized form of b-catenin during the second transition positively influences pancreatic progenitor proliferation, resulting in increased pancreas organ size [12] . Collectively, these findings suggest that temporal and spatial regulation of the Wnt/b-catenin signaling pathway plays a critical role during pancreatic development and islet homeostasis and that compensatory mechanisms might be in place in the Tcf7l2 knock-out model [4, 13] . Additional mechanistic studies are needed to explain the discrepancies among the different mouse models in terms of compensation in the Lef/Tcf transcription factor family, genetic background and efficiency of gene ablation or inhibition. Overall, accumulating evidence has emphasized the importance of Wnt/b-catenin signaling pathway in b-cell development and homeostasis. In human, genetic and metabolic phenotyping clearly reveals that subjects carrying TCF7L2 polymorphisms display insulin secretion defects in the presence of normal incretin plasma levels [14] , suggesting an autonomous role of WNT/TCF7L2 signaling in b-cells and making it an attractive target for development of novel therapies for diabetes. In the future, the key to mechanistic understanding will lie in the investigation of a suitable human model system to unravel WNT/ TCF7L2 function in b-cell homeostasis.
